Stabilized Amyloid-Beta Oligomers Using Disaccharide Buffer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Stabilized compositions of amyloid-β (Aβ) oligomers are needed to overcome the instability and aggregation issues of Aβ peptides, which hinder research on Alzheimer's disease (AD) due to their thermodynamic instability and tendency to form higher-order structures, making it difficult to maintain consistent oligomer compositions over time.
Innovation Solution
The development of stabilized Aβ oligomer compositions using a buffer comprising sodium phosphate, glycine, and a disaccharide, such as sucrose or trehalose, which maintains a substantial percentage of soluble Aβ oligomers for extended periods, preventing fibril formation and aggregation, and allowing for reproducible experiments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If Aβ oligomers are prepared in aqueous solution, then they can be studied in native conditions, but they undergo conformational changes and aggregate to form higher-order structures over time
Solution Approach 1:
The patent introduces a stabilizing agent (such as a metal ion, small molecule, or polymer) that acts as an intermediary between Aβ oligomers and the aqueous environment. This stabilizing agent binds to the oligomers and prevents their aggregation into higher-order structures, while still allowing the oligomers to maintain their native conformation and solubility for study.
Solution Approach 2:
The patent modifies physical or chemical parameters of the Aβ oligomer system, such as pH, ionic strength, temperature, or the addition of stabilizing agents, to alter the thermodynamic stability landscape. These parameter changes prevent the conformational transitions and aggregation that normally occur in aqueous solutions, thereby maintaining oligomer composition stability over time.
2Duration of action of stationary object
If Aβ oligomers are stored for extended periods, then more time is available for experiments, but the oligomer composition changes and variability increases
Solution Approach 1:
The patent performs preliminary stabilization of the Aβ oligomers before storage by introducing stabilizing agents or modifying conditions to prevent degradation pathways. This preliminary action ensures that the oligomers remain compositionally stable throughout extended storage periods, maintaining experimental reproducibility without requiring fresh preparations.
3Quantity of substance
If Aβ peptides are allowed to aggregate spontaneously, then oligomers can form at low concentrations, but the oligomers are metastable and difficult to maintain in consistent compositions
Solution Approach 1:
The patent applies preliminary anti-action by introducing stabilizing agents or modifying environmental conditions to counteract the spontaneous aggregation tendency of Aβ peptides. This prevents the metastable oligomers from transitioning to higher-order structures, maintaining consistent compositions even at low concentrations where spontaneous formation occurs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stabilized Aβ oligomer compositions remain stable for 15-30 days at 4°C or up to 6-9 months as a lyophilized powder, reducing variability and enabling more reliable research on AD, including diagnostic assays and therapeutic agent screening.
Implementation Method 1
a buffer comprising sodium phosphate, glycine, and a disaccharide, such as sucrose or trehalose, which maintains a substantial percentage of soluble Aβ oligomers for extended periods, preventing fibril formation and aggregation
Data Source
AI summary
The present invention pertains to stabilized Aβ oligomer compositions. Methods for generating stabilized Aβ oligomer compounds are also provided herein. Additionally, screening assays employing the Aβ oligomer compounds and methods for generating therapeutics with the Aβ oligomers are also provided. In a particular embodiment, the Aβ oligomer described herein is comprised of Aβ42 peptide.